Search results
9 hours ago · The treatment is available to adults with factor IX clotting levels of less than 2% of normal levels who have no history of or current inhibitors. If gene therapy is successful, it should eliminate the need for day-to-day treatment for at least three years and potentially beyond a decade.
9 hours ago · EPKINLY offers an off-the-shelf, T-cell engaging treatment option that enables treatment across practice settings to address high clinical need EPKINLY is the first and only bispecific antibody approved in the U.S. to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or ...
